Reduced Incidence of Severe Palmar-Plantar Erythrodysesthesia and Mucositis in a Prospective Multicenter Phase II Trial with Pegylated Liposomal Doxorubicin at 40 mg/m2 Every 4 Weeks in Previously Treated Patients with Metastatic Breast Cancer

Salah-Eddin Al-Batran,Meerpohl Hg,Gunter von Minckwitz,Akin Atmaca,U. R. Kleeberg,Nadia Harbeck,Werner Lerbs,Detlef Hecker,Jalid Sehouli,Alexander Knuth,Elke Jäger

Reduced Incidence of Severe Palmar-Plantar Erythrodysesthesia and Mucositis in a Prospective Multicenter Phase II Trial with Pegylated Liposomal Doxorubicin at 40 mg/m2 Every 4 Weeks in Previously Treated Patients with Metastatic Breast Cancer

2006

Salah-Eddin Al-Batran
Meerpohl Hg
Gunter von Minckwitz
Akin Atmaca
U. R. Kleeberg
Nadia Harbeck
Werner Lerbs
Detlef Hecker
Jalid Sehouli
Alexander Knuth
Elke Jäger

Purpose: The aim of this study was to assess whether the reduction in the total dose of pegylated liposomal doxorubicin (PLD) per cycle from 50 mg/m2 every 4 weeks to 40

Keywords:

Pegylated Liposomal Doxorubicin
Immunology
Breast cancer
Mucosa disease
Pathology
Doxorubicin
Cancer
Metastasis
Medicine
Mucositis
Metastatic breast cancer
previously treated

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations